跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
拓咨 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Ixekizumab Injection
Approved
生物制品
Ixekizumab Injection
Eli Lilly and Company
🇨🇳 National Medical Products Administration
Approval Date
Sep 10, 2024
Approval ID
8bLXVtpUGIW
Company
Eli Lilly and Company
Type
生物制品
Approval Details
Approval Id
8bLXVtpUGIW
Approval Number
国药准字SJ20190034
Generic Name
依奇珠单抗注射液
Generic Name En
Ixekizumab Injection
Trade Name
拓咨
Drug Type
生物制品
Dosage Form
注射剂
Strength
80mg/mL(自动注射器)
Reg Date
2024-09-10
Expired Date
2029-05-08
Company Name
Eli Lilly and Company
Production Company Name
Eli Lilly and Company
Company Detail Path
/organization/eli-lilly-cdr-cad-hedged
Production Company Detail Path
/organization/eli-lilly-cdr-cad-hedged
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Sep 10, 2024
Approval ID
8bLXVtpUGIW
Type
生物制品
Back to NMPA Approvals